Thymopentin
PreclinicalSmall molecule
Thymopentin is one of 76 small molecule programs targeting HIV-1 infection. It is currently in Preclinical.
3
Indications
8
Total Trials
0
Active Trials
75
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
66 competitors in HIV-1 Infection
#DrugCompanyPhaseTrials
1Tybost
GileadApproved
Oncovin
Eli LillyApproved
Crestor
AstraZenecaApproved
Bayer Aspirin
BayerApproved
Ziagen
GSKApproved
Renvela
SanofiApproved
Istodax
TevaApproved
Emtriva
GileadApproved
Epidiolex
Jazz PharmaceuticalsApproved
Vemlidy
GileadApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
HIV-1 infection2 trials
HIV-12 trials
HIV1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Thymopentin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- IImmunobiology Research Institute